Control of Bone Mass and Remodeling by PTH Receptor Signaling in Osteocytes
Open accessThe DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Abstract
Osteocytes, former osteoblasts buried within bone, are thought to orchestrate skeletal adaptation to mechanical stimuli. However, it remains unknown whether hormones control skeletal homeostasis through actions on osteocytes. Parathyroid hormone (PTH) stimulates bone remodeling and may cause bone loss or bone gain depending on the balance between bone resorption and formation. Herein, we demonstrate that transgenic mice expressing a constitutively active PTH receptor exclusively in osteocytes exhibit increased bone mass and bone remodeling, as well as reduced expression of the osteocyte-derived Wnt antagonist sclerostin, increased Wnt signaling, increased osteoclast and osteoblast number, and decreased osteoblast apoptosis. Deletion of the Wnt co-receptor LDL related receptor 5 (LRP5) attenuates the high bone mass phenotype but not the increase in bone remodeling induced by the transgene. These findings demonstrate that PTH receptor signaling in osteocytes increases bone mass and the rate of bone remodeling through LRP5-dependent and -independent mechanisms, respectively.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Parfitt, A. M., Drezner, M. K., Glorieux, F. H., Kanis, J. A., Malluche, H., Meunier, P. J., Ott, S. M., & Recker, R. R. (1987) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650020617 · Cited by 5,016
Norman, A. W. (1979) · Cited by 3,769
Bone Histomorphometry : Standardization of Nomenclature, Symbols, and Units
PARFITT, A. M., Drezner, M. K., Glorieux, F. H., Kanis, J. А., Malluche, H. H., Meunier, P. J., Ott, S. M., & Recker, R. R. (1987) · Journal of Bone and Mineral Research · Cited by 3,258
Suda, T., Takahashi, N., Udagawa, N., Jimi, E., Gillespie, M. T., & Martin, T. J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0367 · Cited by 2,336
LDL Receptor-Related Protein 5 (LRP5) Affects Bone Accrual and Eye Development
Gong, Y., Slee, R. B., Fukai, N., Rawadi, G., Roman-Roman, S., Reginato, A. M., Wang, H., Cundy, T., Glorieux, F. H., Lev, D., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00571-2 · Cited by 2,235
Weinstein, R. S., Jilka, R. L., Parfitt, A. M., & Manolagas, S. C. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2799 · Cited by 1,753 · cited 1×
“Detection of apoptotic osteoblasts and osteocytes by in situ nickend labeling was performed as previously described [6,78].”
MethodSelf-citation(2020) · Elsevier eBooks · doi:10.1016/c2015-1-01622-2 · Cited by 1,683
Canonical wnt signaling in differentiated osteoblasts controls osteoclast differentiation.
Glass, D. A., Bialek, P., Ahn, J. D., Starbuck, M., Patel, M. S., Clevers, H., Taketo, M. M., Long, F., McMahon, A. P., Lang, R. A., et al. (2005) · Developmental Cell · doi:10.1016/j.devcel.2005.02.017 · Cited by 1,558
Sclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling
Li, X., Zhang, Y., Kang, H., Liu, W., Liu, P., Zhang, J., Harris, S. E., & Wu, D. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413274200 · Cited by 1,366
Cited by
Bonewald, L. F. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.320 · Cited by 2,287
WNT signaling in bone homeostasis and disease: From human mutations to treatments
Baron, R., & Kneissel, M. (2013) · Nature Medicine · doi:10.1038/nm.3074 · Cited by 2,093
Evidence for osteocyte regulation of bone homeostasis through RANKL expression
Nakashima, T., Hayashi, M., Fukunaga, T., Kurata, K., Oh-hora, M., Feng, J. Q., Bonewald, L. F., Kodama, T., Wutz, A., Wagner, E. F., et al. (2011) · Nature Medicine · doi:10.1038/nm.2452 · Cited by 1,778
Manolagas, S. C. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0024 · Cited by 1,200
Self-citationOsteoblast-Osteoclast Communication and Bone Homeostasis
Kim, J.-M., Lin, C., Stavre, Z., Greenblatt, M. B., & Shim, J.-H. (2020) · Cells · doi:10.3390/cells9092073 · Cited by 1,178
The Osteocyte: An Endocrine Cell … and More
Dallas, S. L., Prideaux, M., & Bonewald, L. F. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1026 · Cited by 1,042
Regulation of Phosphate Homeostasis by PTH, Vitamin D, and FGF23
Bergwitz, C., & Jüppner, H. (2010) · Annual Review of Medicine · doi:10.1146/annurev.med.051308.111339 · Cited by 741
Kenkre, J., & Bassett, J. (2018) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/0004563218759371 · Cited by 693
Parathyroid hormone: anabolic and catabolic actions on the skeleton
Silva, B. C., & Bilezikian, J. P. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.03.005 · Cited by 557
Osteoimmunology: The conceptual framework unifying the immune and skeletal systems
Okamoto, K., Nakashima, T., Shinohara, M., Negishi-Koga, T., Komatsu, N., Terashima, A., Sawa, S., Nitta, T., & Takayanagi, H. (2017) · Physiological Reviews · doi:10.1152/physrev.00036.2016 · Cited by 534
“It is also notable that osteocytes highly express the receptors for PTH and vitamin D3, which are believed to be both physiological and pathological inducers of RANKL (118, 358).”
BackgroundPhysiological Bone Remodeling: Systemic Regulation and Growth Factor Involvement
Siddiqui, J. A., & Partridge, N. C. (2016) · Physiology · doi:10.1152/physiol.00061.2014 · Cited by 534
Understanding the Bone in Cancer Metastasis
Fornetti, J., Welm, A. L., & Stewart, S. A. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3618 · Cited by 526
Demonstration of osteocytic perilacunar/canalicular remodeling in mice during lactation
Qing, H., Ardeshirpour, L., Divieti Pajevic, P., Dusevich, V., Jähn, K., Kato, S., Wysolmerski, J., & Bonewald, L. F. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1567 · Cited by 489
Tu, X., Rhee, Y., Condon, K. W., Bivi, N., Allen, M. R., Dwyer, D., Stolina, M., Turner, C. H., Robling, A. G., Plotkin, L. I., et al. (2012) · Bone · doi:10.1016/j.bone.2011.10.025 · Cited by 459
Self-citationRole and mechanism of action of sclerostin in bone
Delgado-Calle, J., Sato, A. Y., & Bellido, T. (2017) · Bone · doi:10.1016/j.bone.2016.10.007 · Cited by 443
Self-citationLavi-Moshayoff, V., Wasserman, G., Meir, T., Silver, J., & Naveh-Many, T. (2010) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00360.2010 · Cited by 441
Osteoblast and osteocyte: Games without frontiers
Capulli, M., Paone, R., & Rucci, N. (2014) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2014.05.003 · Cited by 413
Update on Wnt signaling in bone cell biology and bone disease
Monroe, D. G., McGee-Lawrence, M. E., Oursler, M. J., & Westendorf, J. J. (2012) · Gene · doi:10.1016/j.gene.2011.10.044 · Cited by 392
Osteocyte-Driven Bone Remodeling
Bellido, T. (2014) · Calcified Tissue International · doi:10.1007/s00223-013-9774-y · Cited by 384
“Resorption induced by exclusive activation of the PTH receptor in osteocytes in transgenic mice is also associated to increased RANKL (36-38); and the bone loss induced during lactation, which is accompanied by increased PTHrP, is dependent on the expression of osteocytic PTH receptor (36;39) (Figure 3).”
Self-citationOsteocyte-Related Cytokines Regulate Osteoclast Formation and Bone Resorption
Kitaura, H., Marahleh, A., Ohori, F., Noguchi, T., Shen, W.-R., Qi, J., Nara, Y., Pramusita, A., Kinjo, R., & Mizoguchi, I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145169 · Cited by 380
The Regulation of Bone Metabolism and Disorders by Wnt Signaling
Maeda, K., Kobayashi, Y., Koide, M., Uehara, S., Okamoto, M., Ishihara, A., Kayama, T., Saito, M., & Marumo, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225525 · Cited by 353
New insights into osteoclastogenic signaling mechanisms
Nakashima, T., Hayashi, M., & Takayanagi, H. (2012) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.05.005 · Cited by 342
Sclerostin: Current Knowledge and Future Perspectives
Moester, M. J. C., Papapoulos, S. E., Löwik, C. W. G. M., & van Bezooijen, R. L. (2010) · Calcified Tissue International · doi:10.1007/s00223-010-9372-1 · Cited by 332
Update on Bone Anabolics in Osteoporosis Treatment: Rationale, Current Status, and Perspectives
Baron, R., & Hesse, E. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2332 · Cited by 320
PTH and PTHrP signaling in osteoblasts
Datta, N. S., & Abou-Samra, A. B. (2009) · Cellular Signalling · doi:10.1016/j.cellsig.2009.02.012 · Cited by 295
The Wnt Inhibitor Sclerostin Is Up-regulated by Mechanical Unloading in Osteocytes in Vitro
Spatz, J. M., Wein, M. N., Gooi, J. H., Qu, Y., Garr, J. L., Liu, S., Barry, K. J., Uda, Y., Lai, F., Dedic, C., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.628313 · Cited by 290
Osteocyte RANKL: New insights into the control of bone remodeling
Xiong, J., & O'Brien, C. A. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1547 · Cited by 287
Self-citationOsteocytes mediate the anabolic actions of canonical Wnt/β-catenin signaling in bone
Tu, X., Delgado-Calle, J., Condon, K. W., Maycas, M., Zhang, H., Carlesso, N., Taketo, M. M., Burr, D. B., Plotkin, L. I., & Bellido, T. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1409857112 · Cited by 276
Self-citationBivi, N., Condon, K. W., Allen, M. R., Farlow, N., Passeri, G., Brun, L. R., Rhee, Y., Bellido, T., & Plotkin, L. I. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.548 · Cited by 261
“using the housekeeping genes mitochondrial ribosomal protein S2 (Mrps2) or glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and the ~Ct method.((5)) Primers and probes for floxed-Cx43, CRE recombinase, and RANKL were manufactured by Assays-by-Design (Applied Biosystems, Foster City, CA, USA).”
BackgroundMethodInfluentialSelf-citationCirculating Sclerostin Levels and Bone Turnover in Type 1 and Type 2 Diabetes
Gennari, L., Merlotti, D., Valenti, R., Ceccarelli, E., Ruvio, M., Pietrini, M. G., Capodarca, C., Franci, M. B., Campagna, M. S., Calabrò, A., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2958 · Cited by 272
Rhee, Y., Bivi, N., Farrow, E., Lezcano, V., Plotkin, L. I., White, K. E., & Bellido, T. (2011) · Bone · doi:10.1016/j.bone.2011.06.025 · Cited by 262
Self-citationThe osteocyte as a signaling cell
Delgado-Calle, J., & Bellido, T. (2022) · Physiological Reviews · doi:10.1152/physrev.00043.2020 · Cited by 261
Self-citationSabbagh, Y., Graciolli, F. G., O'Brien, S., Tang, W., dos Reis, L. M., Ryan, S., Phillips, L., Boulanger, J., Song, W., Bracken, C., et al. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1630 · Cited by 254
Woo, S. M., Rosser, J., Dusevich, V., Kalajzic, I., & Bonewald, L. F. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.465 · Cited by 243
“Constitutive PTH receptor activation in osteocytes increases bone mass and reduces sclerostin expression.((23)) PTH treatment was reported to inhibit SOST in MLO-A5 cells.”
BackgroundPTH receptor signaling in osteocytes governs periosteal bone formation and intracortical remodeling
Rhee, Y., Allen, M. R., Condon, K., Lezcano, V., Ronda, A. C., Galli, C., Olivos, N., Passeri, G., O'Brien, C. A., Bivi, N., et al. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.304 · Cited by 208
Self-citationOsteocytic signalling pathways as therapeutic targets for bone fragility
Plotkin, L. I., & Bellido, T. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.71 · Cited by 206
Self-citationBone turnover markers in the management of postmenopausal osteoporosis
Brown, J. P., Albert, C., Nassar, B. A., Adachi, J. D., Cole, D., Davison, K. S., Dooley, K. C., Don-Wauchope, A., Douville, P., Hanley, D. A., et al. (2009) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2009.04.001 · Cited by 204
Effects of PTH on osteocyte function
Bellido, T., Saini, V., & Pajevic, P. D. (2013) · Bone · doi:10.1016/j.bone.2012.09.016 · Cited by 196
Saini, V., Marengi, D. A., Barry, K. J., Fulzele, K. S., Heiden, E., Liu, X., Dedic, C., Maeda, A., Lotinun, S., Baron, R., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.441360 · Cited by 167
Grethen, E., Hill, K. M., Jones, R., Cacucci, B. M., Gupta, C. E., Acton, A., Considine, R. V., & Peacock, M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2280 · Cited by 136
“In a mouse model, PTH increases bone mass by down-regulating sclerostin production in osteocytes (37, 38).”
BackgroundBen-awadh, A. N., Delgado-Calle, J., Tu, X., Kuhlenschmidt, K., Allen, M. R., Plotkin, L. I., & Bellido, T. (2014) · Endocrinology · doi:10.1210/en.2014-1046 · Cited by 114
Self-citationDelgado-Calle, J., Tu, X., Pacheco-Costa, R., McAndrews, K., Edwards, R., Pellegrini, G. G., Kuhlenschmidt, K., Olivos, N., Robling, A., Peacock, M., et al. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3011 · Cited by 114
“To intermittently increase circulating PTH levels, 4-month-old mice received daily injections of PTH (1-34) (100 ng/g/day; Bachem, Torrance, CA, USA) for 28 days.”
BackgroundMethodResultSelf-citationCalcitonin: Physiology or fantasy?
Davey, R. A., & Findlay, D. M. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1869 · Cited by 101
Targeting WNT signaling in the treatment of osteoporosis
Baron, R., & Gori, F. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.04.011 · Cited by 101
Update in new anabolic therapies for osteoporosis
Canalis, E. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2677 · Cited by 85
Connexin 43 hemichannels and intracellular signaling in bone cells
Plotkin, L. I. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00131 · Cited by 66
Self-citationGuerra-Menéndez, L., Sádaba, M. C., Puche, J. E., Lavandera, J. L., de Castro, L. F., de Gortázar, A. R., & Castilla-Cortázar, I. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-271 · Cited by 64
IGF-I induced phosphorylation of PTH receptor enhances osteoblast to osteocyte transition
Qiu, T., Crane, J. L., Xie, L., Xian, L., Xie, H., & Cao, X. (2018) · Bone Research · doi:10.1038/s41413-017-0002-7 · Cited by 59
Uda, Y., Saini, V., Petty, C. A., Alshehri, M., Shi, C., Spatz, J. M., Santos, R., Newell, C. M., Huang, T. Y., Kochen, A., et al. (2021) · Aging · doi:10.18632/aging.203808 · Cited by 20
Bakr, M. M., Kelly, W. L., Brunt, A. R., Paterson, B. C., Massa, H. M., Morrison, N. A., & Forwood, M. R. (2020) · JBMR Plus · doi:10.1002/jbm4.10387 · Cited by 4
“The downregulation of sclerostin has also been linked to the anabolic PTH effect, through reduction of Sost expression, which negatively regulates Wnt signaling.((54,55)) Our study is the first study to investigate the combined effect of intermittent PTH treatment with a concurrent or ceased ALN treatment on the overa…”
Background
Metadata
- Authors
- O'Brien, C. A., Plotkin, L. I., Galli, C., Goellner, J. J., Gortazar, A. R., Allen, M. R., Robling, A. G., Bouxsein, M., Schipani, E., Turner, C. H., Jilka, R. L., Weinstein, R. S., Manolagas, S. C., & Bellido, T.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-08-13
- Volume
- 3
- Issue
- 8
- Pages
- e2942
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2115271834
- Cited by
- 390
- References
- 85
- FWCI
- 11.29
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.